Cholesterol-lowering drugs called statins given to HIV-positive people "suppressed the virus" and replenished CD4+ T cells, "two key measures of health" among HIV-positive people, researchers from the Spanish Council for Scientific Research in Madrid, Spain, reported in the Aug. 16 issue of the Journal of Experimental Medicine
, the Washington Post
reports. Statins, which are widely used to reduce the risk of heart disease, also are administered to HIV-positive people to treat lipodystrophy, a potential side effect of highly active antiretroviral therapy that can cause metabolic changes, including a rise in cholesterol levels and a redistribution of body fat. After testing statins on HIV-infected cells in the laboratory and in mice, immunologist Dr. Gustavo del Real and colleagues administered lovastatin for one month to six HIV-positive people. Among those people, viral levels decreased and T cell counts increased. When the patients discontinued the statin treatment, their viral levels increased, the Post
reports (Washington Post
, 8/17). Statins appear to stop HIV from opening the membranes of healthy cells and moving out of already infected cells, thus restricting the virus from infecting new cells, according to the researchers. "The data suggest that statins can inhibit HIV-1 replication in chronically infected individuals and support future clinical studies of statins as possible antiretroviral agents," the researchers concluded (Fox, Reuters
Back to other news for August 18, 2004
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.